|
Univariate Kaplan-Meier-Analysis
|
Category
|
p-value
|
95% CI
|
|
Chemotherapy adjuvant
|
y/n
|
0.001
|
7.7–10.2
|
|
pN Stage
|
N1 vs N2 + N3
|
0.032
|
4.2–8.2
|
|
Postoperative complications
|
y/n
|
0.046
|
0.0–11.4
|
|
Age (CP)
|
CI of the median
|
0.228
|
9.6–12.2
|
|
Chemotherapy neoadjuvant
|
y/n
|
0.338
|
8.9–14.1
|
|
pT Stage
|
T1 vs. T2-T4
|
0.621
|
8.9–11.8
|
|
Grading
|
G1 + G2 vs. G3
|
0.270
|
10.4–19.2
|
|
Tumor size (CP)
|
CI of the median
|
0.780
|
9.3–12.2
|
|
Resection volume (CP)
|
CI of the median
|
0.510
|
10.8–18.9
|
|
N° dissected lymph nodes (CP)
|
CI of the median
|
0.348
|
8.2–11.1
|
|
N° positive lymph nodes
|
1–3 vs. > 3
|
0.164
|
6.2–10.6
|
|
Hormonal therapy
|
y/n
|
0.889
|
9.1–11.5
|
|
Radiation SCRT
|
y/n
|
0.762
|
11.5–18.1
|
|
Radiation boost
|
y/n
|
0.332
|
9.8–19.8
|
|
Cardiovascular comorbidity
|
y/n
|
0.512
|
10.2–19.4
|
|
Other comorbidities
|
y/n
|
0.927
|
4.9–12.5
|
|
Tumor recurrence (total)
|
y/n
|
0.949
|
7.2–14.1
|
|
Multivariate Cox-Regression-Analysis
|
Patients with BCRL
|
p-value
|
HR; 95% CI
|
|
Chemotherapy adjuvant
|
58/133 (43.6%)
|
0.005
|
2.5; 0.21–0.76
|
|
Postoperative complications
|
5/9 (55.6%)
|
0.083
|
2.3; 0.18–1.11
|
|
pN Stage
|
16/35 (54.7%)
|
0.119
|
1.6; 0.32–1.10
|
